Company: ARTL
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001640334-25-001429
Chunk: 389

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 389
---
   -   55   -   -   55 Stock based compensation  -   -   213   -   -   213 Net loss for the period  -   -   -   (2,483)  -   (2,483)Balance, March 31, 2024  538  $1  $52,532  $(42,793) $(203) $9,537                          Stock based compensation  -   -   195   -   -   195 Net loss for the period  -   -   -   (2,433)  -   (2,433)Balance, June 30, 2024  538  $1  $52,727  $(45,226) $(203) $7,299 

 5Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

   Six months ended     June 30,    2025  2024        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(5,593) $(4,916)Adjustments to reconcile net loss to net cash used in operating activities:        Stock-based compensation  342   408 Net change in fair value of trading marketable securities  -   (185)Non-cash lease expense  17   16 Amortization of debt discounts and debt issuance costs  54   - Changes in operating assets and liabilities:        Prepaid expenses and other current assets  58   40 Accounts payable and accrued liabilities  3,046   (368)Accounts payable - related parties  (36)  14 Accrued interest  18   - Fixed cash payments related to operating leases  (17)  (14)Net cash used in operating activities  (2,111)  (5,005)         CASH FLOWS FROM INVESTING ACTIVITIES        Investment in trading marketable securities  -   (481)Proceeds from disposition of marketable securities  -   3,500 Net cash provided by